Cargando…

A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice

Introduction: Esketamine (Esk) (S(+)-ketamine) is now used as an alternative to its racemic mixture, i. e., ketamine in anesthesia. Esk demonstrated more powerful potency and rapid recovery in anesthesia and less psychotomimetic side effects comparing with ketamine, but Esk could still induce psycho...

Descripción completa

Detalles Bibliográficos
Autores principales: Chu, Qinjun, Zhu, Kuicheng, Bai, Yafan, Shang, Huijie, Zhang, Dongqing, Zhao, Mingming, Zheng, Ping, Jin, Xiaogao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545873/
https://www.ncbi.nlm.nih.gov/pubmed/34712126
http://dx.doi.org/10.3389/fnhum.2021.735569
_version_ 1784590081501167616
author Chu, Qinjun
Zhu, Kuicheng
Bai, Yafan
Shang, Huijie
Zhang, Dongqing
Zhao, Mingming
Zheng, Ping
Jin, Xiaogao
author_facet Chu, Qinjun
Zhu, Kuicheng
Bai, Yafan
Shang, Huijie
Zhang, Dongqing
Zhao, Mingming
Zheng, Ping
Jin, Xiaogao
author_sort Chu, Qinjun
collection PubMed
description Introduction: Esketamine (Esk) (S(+)-ketamine) is now used as an alternative to its racemic mixture, i. e., ketamine in anesthesia. Esk demonstrated more powerful potency and rapid recovery in anesthesia and less psychotomimetic side effects comparing with ketamine, but Esk could still induce psychological side effects in patients. This study was to investigate whether dexmedetomidine (Dex) can attenuate the Esk-induced neuronal hyperactivities in Kunming mice. Methods: Dexmedetomidine 0.25, 0.5, and 1 mg/kg accompanied with Esk 50 mg/kg were administrated on Kunming mice to assess the anesthesia quality for 1 h. The indicators, such as time to action, duration of agitation, duration of ataxia, duration of loss pedal withdrawal reaction (PWR), duration of catalepsy, duration of righting reflex (RR) loss, duration of sedation, were recorded for 1 h after intraperitoneal administration. The c-Fos expression in the brain was detected by immunohistochemistry and Western Blot after 1 h of administration. Considering the length of recovery time for more than 1 h in Dex and Dex with Esk groups, other mice were repeatedly used to evaluate recovery time from the administration to emerge from anesthesia. Results: Dexmedetomidine dose-dependently increased recovery time when administrated with Esk or alone. Dex combined with Esk efficiently attenuated the duration of agitation, ataxia, and catalepsy. Dex synergically improved the anesthesia of Esk by increasing the duration of sedation, loss of RR, and loss of PWR. Esk induced the high expression of c-Fos in the cerebral cortex, hippocampus, thalamus, amygdala, hypothalamus, and cerebellum 1 h after administration. Western Blot results indicated that Dex at doses of 0.25, 0.5, and 1 mg/kg could significantly alleviate the Esk-induced c-Fos expression in the mice brain. Conclusion: Dexmedetomidine ranged from 0.25 to 1 mg/kg could improve the anesthesia quality and decreased the neuronal hyperactivities and the overactive behaviors when combined with Esk. However, Dex dose-dependently increased the recovery time from anesthesia. It demonstrated that a small dose of Dex 0.25 mg/kg could be sufficient to attenuate Esk-induced psychotomimetic side effects without extension of recovery time in Kunming mice.
format Online
Article
Text
id pubmed-8545873
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85458732021-10-27 A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice Chu, Qinjun Zhu, Kuicheng Bai, Yafan Shang, Huijie Zhang, Dongqing Zhao, Mingming Zheng, Ping Jin, Xiaogao Front Hum Neurosci Human Neuroscience Introduction: Esketamine (Esk) (S(+)-ketamine) is now used as an alternative to its racemic mixture, i. e., ketamine in anesthesia. Esk demonstrated more powerful potency and rapid recovery in anesthesia and less psychotomimetic side effects comparing with ketamine, but Esk could still induce psychological side effects in patients. This study was to investigate whether dexmedetomidine (Dex) can attenuate the Esk-induced neuronal hyperactivities in Kunming mice. Methods: Dexmedetomidine 0.25, 0.5, and 1 mg/kg accompanied with Esk 50 mg/kg were administrated on Kunming mice to assess the anesthesia quality for 1 h. The indicators, such as time to action, duration of agitation, duration of ataxia, duration of loss pedal withdrawal reaction (PWR), duration of catalepsy, duration of righting reflex (RR) loss, duration of sedation, were recorded for 1 h after intraperitoneal administration. The c-Fos expression in the brain was detected by immunohistochemistry and Western Blot after 1 h of administration. Considering the length of recovery time for more than 1 h in Dex and Dex with Esk groups, other mice were repeatedly used to evaluate recovery time from the administration to emerge from anesthesia. Results: Dexmedetomidine dose-dependently increased recovery time when administrated with Esk or alone. Dex combined with Esk efficiently attenuated the duration of agitation, ataxia, and catalepsy. Dex synergically improved the anesthesia of Esk by increasing the duration of sedation, loss of RR, and loss of PWR. Esk induced the high expression of c-Fos in the cerebral cortex, hippocampus, thalamus, amygdala, hypothalamus, and cerebellum 1 h after administration. Western Blot results indicated that Dex at doses of 0.25, 0.5, and 1 mg/kg could significantly alleviate the Esk-induced c-Fos expression in the mice brain. Conclusion: Dexmedetomidine ranged from 0.25 to 1 mg/kg could improve the anesthesia quality and decreased the neuronal hyperactivities and the overactive behaviors when combined with Esk. However, Dex dose-dependently increased the recovery time from anesthesia. It demonstrated that a small dose of Dex 0.25 mg/kg could be sufficient to attenuate Esk-induced psychotomimetic side effects without extension of recovery time in Kunming mice. Frontiers Media S.A. 2021-10-12 /pmc/articles/PMC8545873/ /pubmed/34712126 http://dx.doi.org/10.3389/fnhum.2021.735569 Text en Copyright © 2021 Chu, Zhu, Bai, Shang, Zhang, Zhao, Zheng and Jin. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Human Neuroscience
Chu, Qinjun
Zhu, Kuicheng
Bai, Yafan
Shang, Huijie
Zhang, Dongqing
Zhao, Mingming
Zheng, Ping
Jin, Xiaogao
A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice
title A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice
title_full A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice
title_fullStr A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice
title_full_unstemmed A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice
title_short A Single Low Dose of Dexmedetomidine Efficiently Attenuates Esketamine-Induced Overactive Behaviors and Neuronal Hyperactivities in Mice
title_sort single low dose of dexmedetomidine efficiently attenuates esketamine-induced overactive behaviors and neuronal hyperactivities in mice
topic Human Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8545873/
https://www.ncbi.nlm.nih.gov/pubmed/34712126
http://dx.doi.org/10.3389/fnhum.2021.735569
work_keys_str_mv AT chuqinjun asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhukuicheng asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT baiyafan asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT shanghuijie asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhangdongqing asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhaomingming asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhengping asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT jinxiaogao asinglelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT chuqinjun singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhukuicheng singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT baiyafan singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT shanghuijie singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhangdongqing singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhaomingming singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT zhengping singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice
AT jinxiaogao singlelowdoseofdexmedetomidineefficientlyattenuatesesketamineinducedoveractivebehaviorsandneuronalhyperactivitiesinmice